Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales - Milestone Pharmaceuticals (NASDAQ:MIST
Milestone Pharmaceuticals kazancı $0,43 ile beklentilere göre daha kötü, kâr ise beklentilere göre düşük
Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Milestone Pharmaceuticals (NASDAQ:MIST)